ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / ADUS
WGS (47) PRVA (53) AVAH (65) TDOC (55) ⌘ Pro Terminal β†’

Addus HomeCare Corporation (ADUS) β€” RQD Stock Rating Cockpit

$125.54 +0.97% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $126.06

Addus HomeCare Corporation (ADUS) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (33% profit margin, 9% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

πŸ“Š Historical Track Record: Scores of 74/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.3% avg 90D alpha vs SPY β€’ 69.4% hit rate) β†’
ROARABLE B β€’ BUY Cap $2.34B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ADUS Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is ADUS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Addus HomeCare Corporation (NASDAQ: ADUS) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $125.54 (+0.97% 1D, market cap $2.34B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, ADUS ranks #41 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does ADUS compare to WGS and PRVA in the Health Care sector?
β–Ό

Within the Health Care sector (Medical/Nursing Services), ADUS carries a Roarable B (74/100 RQD), trailing P/E of 24.2x, gross margin of 32.5%, and ROIC of 9.1%. By comparison, WGS (GeneDx Holdings Corp. (Class A)) holds a D grade (47/100 RQD, P/E N/A, ROIC -4.1%, cap $2.06B) and PRVA (Privia Health Group Inc.) posts a D+ grade (53/100 RQD, P/E 122.6x, ROIC 10.5%, cap $2.74B). Among the 5-stock peer group, ADUS leads on earnings multiple (24.2x) while AVAH leads on capital efficiency (15.7% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ADUS?
β–Ό

Per ADUS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001468328), Addus HomeCare Corporation generated $1.42B in revenue (+23.2% YoY), $95.9M in net income, and $103.8M in free cash flow against $1.44B in total assets and $121.0M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $126.05 (+0.41%)🧬 Cannibal Buyback (-2.08% YoY Shares)βš™οΈ Cash Engine: 12/20 (C-) β€’ 7.3% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 74/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.3% avg 90D alpha vs SPY β€’ 69.4% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERBUY β€’ B
025507510074
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B Β· Rk B
Cash (12)Whales (17)SEC (15)Macro (15)CEO (15)
Each axis scored 0–20
12M PRICE TARGET CONE+7.2% Base Target
$159 Bull$135 Base$103 Bear
πŸ“¬ FREE ADUS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for ADUS)Realized 20D OHLCV Swing Band: Β±4.7%
Deterministic 5-Pillar Attribution (74/100 Composite)
πŸ” WHY ADUS SCORES 74/100 (B) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Whale & Options Positioning+17/20 pts (23% of score)

20D Institutional Volume Accumulation (Β±4.7% realized swing band)

β–² #2 Bullish Driver: SEC 10-K Forensic Risk+15/20 pts (20% of score)

Altman Z-Score 5.83 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 9/9

β–Ό #1 Drag / Risk Factor: Cash Engine Quality12/20 pts (-8 pt drag)

Capital intensity & 9.7% operating margin leave 8 pts on the table

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
66
Grade B-$114.53+3.1% Next Q
Q2 (-2Q)
69
Grade B-$118.03+2.7% Next Q
Q3 (-1Q)
71
Grade B$121.24+3.5% Next Q
Current
74
Grade B$125.54+7.3% Hist 90D Ξ±
Trajectory: B- (66) β†’ B (74)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

βš”οΈ Adversarial Opposing Case: Why the ADUS Bull Thesis Could Fail

Gideon Ashmere Forensic Desk β†’

Even with a 74/100 (B) score, ADUS faces multiple-compression risk if 24.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) β€” any gross margin slip below 30.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($117.17) or 200D SMA ($106.52) invalidates the momentum regime and cuts Target Base ($134.58) toward Bear Floor ($102.94).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ADUSβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œADUS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 74%NO 26%Trade / Inspect Odds β†’
RSI-14 MOMENTUMOVERBOUGHT (>70)
70.230 Oversold Β· 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
5.83>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
9 / 99-Pt Accounting
52-WEEK LASER RANGE97% OF RANGE
L: $88$125.54H: $127
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (33% profit margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20
2. Big Money & Insiders● BUYING
Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: B+RQD 32 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: BRQD 30 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on ADUS

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (60)

9.1% ROIC with 32.5% gross margin and 4.47% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (75)

Altman-Z 5.83 and Piotroski 9/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BULLISH (78)

32/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like ADUS
  • βœ“Big institutional funds and options desks are actively positioning on the bullish side.
  • βœ“Company leadership has skin in the game with net positive insider conviction.
  • βœ“Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Broader market pullbacks can still drag down strong stocks in the short run.
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (ADUS Tape Review)

  • βœ“Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • βœ“Forensic Red-Light accounting & dilution traps to review on your watchlist
  • βœ“Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
ADUS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +25.39%⚑ TESTING RESISTANCE
2026-11-03O $124.3H $125.5L $124.3C $125.5VOL 300.4K
RES: $126.8SUP: $111.2SMA50: $117.2SMA200: $106.5
$129.3$118.1$106.9$95.68$84.47RES $126.8SUP $111.2$125.52026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ADUS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ ADUS Butterfly Map β†’ + Track ADUS β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
17.9%/yr Implied 5Y Growth

vs. +23.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ADUS today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for ADUS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ADUS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ADUS)

Health Care Rank #41 of 1016 βš”οΈ WGS vs ADUS Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (ADUS vs. WGS, PRVA, AVAH, TDOC)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Addus HomeCare Corporation (ADUS) ranks #41 by composite RQD confidence (74/100, grade B) and #227 by equity capitalization ($2.34B). Within this direct 5-issuer industry benchmark cohort, ADUS leads on earnings valuation at 24.2x trailing P/E, while AVAH leads on capital efficiency and profitability with 15.7% ROIC and 33.3% gross margin. ADUS currently leads its immediate peer cohort in composite quantitative strength at 74/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ADUS ACTIVE
Addus HomeCare Corporation
B 74/100 24.2x 32.5% 9.1% +0.97% $2.34B Benchmark Subject
WGS
GeneDx Holdings Corp. (Class A)
D 47/100 β€” 69.7% -4.1% -2.76% $2.06B /wgs-vs-adus β†’
PRVA
Privia Health Group Inc.
D+ 53/100 122.6x β€” 10.5% -2.34% $2.74B /prva-vs-adus β†’
AVAH
Aveanna Healthcare Holdings Inc.
C 65/100 β€” 33.3% 15.7% -0.75% $2.87B /avah-vs-adus β†’
TDOC
Teladoc Health Inc.
D+ 55/100 β€” β€” -17.0% -2.52% $1.55B /tdoc-vs-adus β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001468328

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Addus HomeCare Corporation (ADUS) reported GAAP revenue of $1.42B (+23.2% vs. FY2024 revenue of $1.15B , and +34.4% cumulative change since FY2023) , GAAP net income of $95.9M, operating cash flow of $111.5M, and free cash flow of $103.8M (-6.0% YoY). On the balance sheet, ADUS closed FY2025 with $1.44B in total assets against $121.0M in total debt (Altman Z-Score: 5.83, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.42B $95.9M $111.5M $103.8M $1.44B $121.0M
FY2024 (FY) 2024-12-31 $1.15B $73.6M $116.4M $110.4M $1.41B $218.4M
FY2023 (FY) 2023-12-31 $1.06B $62.5M $112.2M $112.2M β€” β€”

3. ADUS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ADUS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Addus HomeCare Corporation (NASDAQ: ADUS) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $125.54 (+0.97% 1D, market cap $2.34B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 17/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, ADUS ranks #41 in composite RQD confidence.

How does ADUS compare to WGS and PRVA in the Health Care sector?

Within the Health Care sector (Medical/Nursing Services), ADUS carries a Roarable B (74/100 RQD), trailing P/E of 24.2x, gross margin of 32.5%, and ROIC of 9.1%. By comparison, WGS (GeneDx Holdings Corp. (Class A)) holds a D grade (47/100 RQD, P/E N/A, ROIC -4.1%, cap $2.06B) and PRVA (Privia Health Group Inc.) posts a D+ grade (53/100 RQD, P/E 122.6x, ROIC 10.5%, cap $2.74B). Among the 5-stock peer group, ADUS leads on earnings multiple (24.2x) while AVAH leads on capital efficiency (15.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ADUS?

Per ADUS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001468328), Addus HomeCare Corporation generated $1.42B in revenue (+23.2% YoY), $95.9M in net income, and $103.8M in free cash flow against $1.44B in total assets and $121.0M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ADUS trading relative to its 50-day, 200-day, and 52-week technical levels?

ADUS last traded at $125.54 (+0.97% on volume of 300,403 shares), positioning the stock +7.14% above its 50-day simple moving average ($117.17) and +17.86% above its 200-day simple moving average ($106.52). Across its 52-week range of $87.95 to $126.62, ADUS sits at the 97.2% percentile with a 14-day RSI of 70.2 (OVERBOUGHT (>70)) and an implied next-earnings move of Β±4.7% ($119.64 to $131.44).

ADUS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Should I buy, hold, or sell ADUS stock right now?

Addus HomeCare Corporation (ADUS) currently earns a Roarable Rating of B (Buy β€” BUY) with 74/100 RQD Confidence. High-quality cash engine (33% profit margin, 9% return on capital) with steady institutional support.

What is ADUS's 12-month price target and RQD AI Jury consensus?

ADUS's 12-month base price target is $134.58 (range $102.94 to $158.8), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: ADUS RQD Cockpit ADUS 12M Forecast ADUS Earnings & Move ADUS Dividends & DRIP ADUS Insiders & 13F ADUS Whale Options ADUS Profit Sankey ADUS News & Why
ROARABLE RATING BRIEF β€’ RQD 74/100 (B) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

ADUS β€” Addus HomeCare Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:26:04Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ADUS carries an RQD Score of 73, a letter grade of B, and the verdict label "Roarable Buy β€” Good Risk/Reward." The five pillars are:

  • Fundamental Cash Engine: 12 / 20. Per the RQD rating, this pillar cites ROIC of 9.1% and FCF yield of 4.47%. This is the lowest-scoring pillar, indicating that cash generation relative to capital and valuation is only moderately supportive of the thesis. An investor should note that the FCF yield of 4.47% is the main valuation anchor for cash-based reasoning.
  • Whale 13F Flow: 16 / 20. The RQD rating describes institutional accumulation and options positioning as a relative strength. This suggests larger holders have been net constructive, though the holder-level data supporting this pillar is not itemized in the source data.
  • Insider Conviction: 15 / 20. Per the RQD rating, SEC Form 4 and Congressional PTR cluster flow contribute a moderately positive signal. The underlying transaction detail is not itemized in the source data.
  • Macro Regime Fit: 15 / 20. Per the RQD rating, beta is 1.0 and sector sensitivity is cited. A beta of 1.0 means the stock is described as moving in line with the broad market, so macro regime shifts would be expected to affect it roughly proportionally.
  • Forensic Balance Sheet: 15 / 20. Per the RQD rating, Altman Z is 5.83, Piotroski F is 9/9, and Debt/Equity is 0.11. These are the strongest forensic readings in the source data and point to a low-leverage, financially sound profile.

For a prospective investor evaluating the stock today, the pillar mix implies that the case rests more on balance sheet strength and institutional/insider positioning than on cash-generation efficiency. Valuation is a tradeoff: per the market data, P/E (TTM) is 24.2 versus a forward P/E of 20.3, which implies expected earnings growth is embedded in the forward estimate, while EV/EBITDA of 16.8 is not compared to a peer benchmark in the source data. The upside drivers cited are the forensic strength and positioning flow; the main constraint is the 9.1% ROIC and 4.47% FCF yield. Ripple effects from the sector are not quantified in the source data. This analysis is educational and not personalized financial advice.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
124.34$2.32B24.220.316.85.140%1.0$87.95 - $126.629.1%

Recent Catalysts & News Wire Analysis

Per the recent news feed, all six items are flagged YELLOW and classified as MARKET WIRE, sourced from Yahoo Finance, TradingView, Simply Wall St, and Stock Traders Daily. Themes include market action and institutional positioning coverage, a Q3 earnings preview, and an announcement of a Third Quarter 2026 earnings release and conference call. Headlines are general market commentary; no specific operational, contract, or regulatory catalyst is detailed in the source summaries. Risk watch items: the upcoming Q3 earnings release is the one dated event named in the feed. Proprietary signals: Not available in source data, per the Butterfly Supply-Chain Graph.

Open Questions

  • What are the specific service lines and payer mix behind FY 2025 revenue growth, and how much depends on government reimbursement?
  • What are the reported EPS and cash balances for FY 2025 and FY 2023, which are currently marked as unavailable?
  • What is the composition and timing of the institutional, insider, and Congressional transactions underlying the RQD pillar scores?
  • How does EV/EBITDA of 16.8 and ROIC of 9.1% compare with peers, given no peer or analyst benchmark is included in the source data?
  • What drove the decline in FCF from $112.2M to $103.8M despite rising net income?

ADUS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Addus HomeCare Corporation (ADUS) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to ADUS Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ADUS Bull vs. Bear Conversation Board β€” What's Your Call at $125.54?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ADUS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ADUS:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk πŸ‚ BULLISH 🎯 Target: $146.72 (+18.0%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is ADUS (B β€’ RQD 73/100) a Buy at $124.34?

Welcome to the ADUS (Addus HomeCare Corporation) Roar Pit. Current RQD Composite is 73/100 (Roarable Buy β€” Good Risk/Reward) in Medical/Nursing Services. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $98.23 (-21.0%)
Spot @ $124.34

Pump the brakes on ADUS β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ADUS, but look at what you are paying: 24.2x trailing P/E with 32.5% gross margins. Unless Addus HomeCare Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $147.96 (+19.0%)
Spot @ $124.34

ADUS cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ADUS, the market is fixating on short-term headline noise in Medical/Nursing Services and ignoring the balance sheet and cash flow trajectory. At $124.34 (52-wk range $87.95 - $126.62), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%